Press

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Sep 27 • 4 min read

Quick Take: The research will mark the first psychedelic treatment program for Hypoactive Sexual Desire Disorder (HSDD). Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research in psychedelics, introduces its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. …

Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders

Sep 27 • 4 min read

Quick Take: The round was led by ARTIS Ventures, RA Capital Management, and OMX Ventures. The proceeds will advance two of their leading psychedelic candidates. Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the closing of a $70 million Series A financing round. The round was led by ARTIS Ventures, RA Capital Management, and…

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Sep 24 • 3 min read

Quick Take: The findings include psilocybin interactions with SSRIs and LSD vs. psilocybin dosages in a clinical setting. Mind Medicine Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany. These investigator-initiated studies are being conducted as part of MindMed’s…

Numinus Completes Acquisition of Neurology Centre of Toronto

Sep 23 • 4 min read

Quick Take: The clinic will continue operation under the name “Neurology Centre of Toronto by Numinus”. Numinus Wellness Inc. (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced it has closed its acquisition of the Neurology Centre of Toronto (NCT), a leading Canadian provider of clinical neurologic care. The purchase…

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

Sep 22 • 4 min read

Quick Take: FSD Pharma has closed on the acquisition of Lucid Psycheceuticals, a company focused on developing psychedelic medicine for neurodegenerative diseases. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435